135684-35-4

Upstream product

• 135684-34-3 ethyl (2S,3R)-3-(t-butyldimethylsilyloxy)-2-(4-methoxybenzylaminomethyl)butanoate 
• 2633-66-1 2-mesitylmagnesium bromide 
• 2746-25-0 p-Methoxybenzyl bromide 
• 109323-90-2 (1'R,3S)-3-<1'-<(tert-butyldimethylsilyl)oxy>ethyl>azetidin-2-one 

Downstream Products

• 1335557-90-8 (3S)-1-(4-methoxybenzyl)-[(1R)-hydroxyethyl]azetidin-2-one 
• 1335557-91-9 (3S)-1-(4-methoxybenzyl)-[(1R)-(4-phenylbutoxy)ethyl]azetidin-2-one 
• 1335557-92-0 1-(4-methoxybenzyl)-3-[(1R)-(4-phenylbutoxy)ethyl]azetidine 
• 1335557-93-1 3-[(1R)-(4-phenylbutoxy)ethyl]azetidine 
• 1335557-84-0 1-(pent-4-enoyl)-3-[1(R)-(4-phenylbutoxy)ethyl]azetidine 

Relevant academic research and scientific papers

SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (h FAAH): Evidence of a nonhydrolytic process

The endocannabinoid hydrolyzing enzyme FAAH uses a nonclassical catalytic triad (namely, Ser-Ser-Lys instead of Ser-Asp-His) to cleave its endogenous substrates. Because inhibiting FAAH has a clear therapeutic potential, we previously developed β-lactam-t

Enzymatic process for preparing optically active 3-substituted azetidinones

Preparation of optically active 3-substituted azetidinones of the formula (I) STR1 in which R1 is a hydroxy-protective group wherein an allylic alcohol of the formula (II) STR2 is acylated, then subjected to asymmetric enzymatic hydrolysis yiel